Your session is about to expire
← Back to Search
Venetoclax + Chemotherapy for Leukemia
Study Summary
This trial is studying how well Venetoclax and standard chemotherapy work in treating patients with acute lymphoblastic leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 389 Patients • NCT02005471Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My leukemia is Ph-positive ALL, Burkitt's, or lymphoblastic lymphoma.I am 60 or older with acute lymphoblastic leukemia that has not been treated and affects over 20% of my bone marrow.I have symptoms or untreated issues with my brain or spinal cord.I cannot take medications by mouth due to a digestive condition.I have had cancer before, but it's been treated or in remission for 2 years, except for non-melanoma skin cancer or carcinoma in situ.I have not eaten grapefruit, Seville oranges, or star fruit in the last 3 days.I do not have any infections that are currently uncontrolled.I have hepatitis B, hepatitis C, or HIV.I haven't had chemotherapy, radiotherapy, or experimental treatments in the last 14 days, except for specific allowed medications.I am currently taking warfarin.I am 18 or older with acute lymphoblastic leukemia that has not improved after treatment, can move around, and have more than 5% cancer cells in my bone marrow.I have not had major surgery or radiation therapy in the last 4 weeks.I do not have severe heart disease or recent major heart events.I have been treated with venetoclax before.I haven't taken strong CYP3A affecting drugs within 3 days before starting venetoclax.My heart's pumping ability is below 40%.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Venetoclax + Chemotherapy
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Are there any vacancies left in this clinical experiment?
"Affirmative, the data hosted on clinicaltrials.gov implies that this medical research is actively looking for candidates to enroll in the study. This trial was first posted on October 30th 2017 and saw its most recent update take place on October 3rd 2022. The team behind this investigation must recruit 82 participants across three sites."
Are there any other investigations that have taken place in regards to Venetoclax?
"Venetoclax was pioneered by M D Anderson Cancer Center in the year 2014. Since then, there have been 56 successful trials and 219 ongoing ones, many of which are located within Houston's metropolitan area."
What is the aggregate participant enrollment for this clinical trial?
"To fulfill the study requirements, 82 fitting subjects are needed to partake in this clinical trial. Patients can join from MD Anderson Cancer Center located in Houston, Texas and Dana Farber Cancer Institute based in Boston, Massachusetts."
Share this study with friends
Copy Link
Messenger